Study S002151

A Two Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of the Combined Use of Once Daily 10mg Dapagliflozin and Once Weekly 1.0mg Semaglutide in Kidney Transplant Recipients

ClinicalTrials.gov record

Registration

Registration: NCT05938712
Acronym: HALLMARK
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 20
Start: 2023-10-24
Primary completion: 2027-10-01
Lead sponsor: University Health Network, Toronto
Conditions: Kidney Transplant Recipients
Interventions: DRUG:Dapagliflozin 10 MG; DRUG:Semaglutide, 1.0 mg/mL
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Proximal tubular natriuresis with combination therapy [From baseline to combination therapy end (24 weeks)]
Proximal tubular natriuresis with monotherapy [From baseline to monotherapy end (12 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.